• DOI:10.3928/01477447-20160526-02
• Corpus ID: 23180797

Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.

@article{Moskal2016MetaanalysisOI,
  title={Meta-analysis of Intravenous Tranexamic Acid in Primary Total Hip Arthroplasty.},
  author={Joseph T. Moskal and Susan G. Capps},
  journal={Orthopedics},
  year={2016},
  volume={39 5},
  pages={
          e883-92
        }
}

• J. Moskal, S. G. Capps
• Published 19 September 2016
• Medicine
• Orthopedics

Previous meta-analyses established that tranexamic acid confers benefits when used during total hip arthroplasty (THA). However, 2 of these meta-analyses included a variety of routes of administration of tranexamic acid in THA (topical, intravenous, oral, and intra-articular), another meta-analysis included a variety of antifibrinolytic drugs (not restricted to a single drug), and the final meta-analysis included nonrandomized controlled trials. This meta-analysis focused on a single medication, tranexamic acid, administered in a specific way, intravenously in patients undergoing primary THA, using data reported only in randomized controlled studies. Outcomes were restricted to blood loss, allogeneic transfusion rates, and complications. Other outcomes, such as return to function or clinical scores, could not be evaluated because of lack of consistent reporting. To better understand the effects of intravenous tranexamic acid in THA on clinical outcomes, such as recovery, return to function, and patient-reported outcome measures, it would be helpful to have more controlled trials examining these measures in a standardized manner. Intravenous tranexamic acid was beneficial for blood loss intraoperatively, blood loss through drains, and total blood loss during hospitalization, in addition to reducing allogeneic transfusion rates. No difference between intravenous tranexamic acid and placebo was found for most complications, except deep venous thrombosis, which showed favorable results with placebo. [Orthopedics.2016; 39(5):e883-e892.].